Abstract
The type I interferon is commonly used in the treatment of multiple sclerosis. However, some effects of this cytokine still remain to be elucidated. The plasmacytoid dendritic cells when activated with TLR 9 agonist produced significant amount of type I interferon and indoleamina 2,3 dioxigenase (IDO). This enzime contribute to the activation of regulatory T lymphocytes, which are impair…